U.S. Markets open in 2 hrs 42 mins
  • S&P Futures

    -52.00 (-1.12%)
  • Dow Futures

    -253.00 (-0.71%)
  • Nasdaq Futures

    -276.25 (-1.77%)
  • Russell 2000 Futures

    -23.40 (-1.08%)
  • Crude Oil

    +1.46 (+1.74%)
  • Gold

    -5.50 (-0.30%)
  • Silver

    -0.03 (-0.12%)

    -0.0013 (-0.1140%)
  • 10-Yr Bond

    0.0000 (0.00%)
  • Vix

    +1.46 (+7.19%)

    -0.0029 (-0.2152%)

    +0.0850 (+0.0742%)

    -937.02 (-2.19%)
  • CMC Crypto 200

    -25.65 (-2.50%)
  • FTSE 100

    -50.12 (-0.66%)
  • Nikkei 225

    -76.27 (-0.27%)

Podcast Corner - Chairman, CEO of Sigyn Therapeutics, Inc. Discusses Treatment of Life-Threatening Conditions Induced by Cytokine Storm Syndrome

  • Oops!
    Something went wrong.
    Please try again later.
·5 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

Point Roberts, Washington and Delta, British Columbia--(Newsfile Corp. - January 25, 2021) - Investorideas.com, a global news source and leading retail investor and trader resource issues a new CEO interview for the Podcast Corner. In today's special edition, Investor Ideas talks to Sigyn Therapeutics, Inc. (OTC Pink: SIGY) Chairman and CEO, Jim Joyce.

Previously, Mr. Joyce was the founder and former Chairman and CEO of Aethlon Medical, Inc.

Listen to today's Podcast:


Listen to Investor Ideas podcasts on Spotify

Mr. Joyce discusses Sigyn Therapeutics vision for addressing life-threatening inflammatory conditions that are precipitated by Cytokine Storm Syndrome stating, "Cytokine Storm Syndrome is a dis-regulated immune response that results in the overproduction of inflammatory cytokines that can induce organ failure and cause death. It can be triggered by a wide range of infectious conditions and is a leading cause of death related to severe COVID-19 infections. It also underlies sepsis, which is the number one cause of in-hospital deaths worldwide and an annual market opportunity that exceeds $20 billion." Mr Joyce added that: "Cytokine Storm Syndrome can also be triggered by non-infectious disease conditions such as an adverse response to drug therapies including emerging cancer immunotherapies."

Mr. Joyce further discussed how the limitations of single-target drugs have created an increased interest in extracorporeal blood purification technologies that can address a broad-spectrum of inflammatory targets, whereas anti-Cytokine drug agents are limited to a single Cytokine target.

Continued: "We really see two pioneering devices and they happen to be associated with public companies. One is the CytoSorb device from CytoSorbents Corporation which has a market value of approximately $400 million. This device is designed to reduce the presence of a broad-spectrum of inflammatory cytokines from circulation."

Continued: "The other device is the Toraymyxin Device which is a product of Toray Industries, Inc. based in Japan. This is one of about several products from Toray that drives a market value of about $10 billion. The Toraymyxin product eliminates circulating endotoxins, which is a potent activator of the cytokine storm."

Continued: "However, it does not address inflammatory Cytokines. Inversely, CytoSorb addresses inflammatory Cytokines but doesn't address endotoxin. So that's something we took into great consideration when we designed Sigyn Therapy to simultaneously address inflammatory Cytokines, endotoxin and much larger CytoVesicles that transport inflammatory Cytokine cargos throughout the circulatory system (OTC Pink: SIGY).

Sigyn Therapeutics is a development-stage therapeutic technology company headquartered in San Diego, California, USA. Their focus is directed toward a significant unmet need in global health; the treatment of life-threatening inflammatory conditions that are precipitated by Cytokine Storm Syndrome. Their mission is to save lives.

Sigyn Therapy™ is a novel blood purification technology designed to mitigate cytokine storm syndrome through the broad-spectrum depletion of inflammatory targets from the bloodstream. Cytokine storm syndrome is the hallmark of sepsis, which is the most common cause of in-hospital deaths and claims more lives each year than all forms of cancer combined. Virus induced cytokine storm (VICS) is associated with high mortality and is a leading cause of SARS-CoV-2 (COVID-19) deaths. Other therapeutic opportunities include, but are not limited to bacteria induced cytokine storm (BICS), acute respiratory distress syndrome (ARDS) and acute forms of liver failure, such as hepatic encephalopathy.

Joyce also discusses his previous leadership role at Aethlon Medical, Inc. where he oversaw the development of the Hemopurifier to treat life-threatening viral infections and address tumor-derived exosomes in cancer patients as a great experience prior to founding Sigyn Therapeutics, Inc.

To learn more, visit www.SigynTherapeutics.com or www.SigynTherapy.com.

About Investorideas.com - News that Inspires Big Investing Ideas Investorideas.com is a recognized news source publishing third party news, research and original financial content. Learn about investing in stocks and sector trends with our news alerts, articles, podcasts and videos, looking at cannabis, crypto, AI and IoT, mining, sports biotech, water, renewable energy and more. Investor Idea's original branded content includes the following podcasts and columns : Crypto Corner , Play by Play sports and stock news column, Investor Ideas Potcasts Cannabis News and Stocks on the Move podcast and column, Cleantech and Climate Change , Exploring Mining the AI Eye.

The Investorideas.com podcasts are also available on iTunes, Spotify, Tunein, Stitcher, Spreaker.com, iHeartRadio and Google Play Music.

Visit the Podcast page at Investorideas.com: https://www.investorideas.com/Audio/.

Investors can trade these stocks and other ideas on our site using our list of top stock trading apps including Robinhood , Acorn, Stash and others.

Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investing involves risk and possible losses. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. Contact management and IR of each company directly regarding specific questions. More disclaimer info: https://www.investorideas.com/About/Disclaimer.asp Disclosure: the distribution of this podcast was paid for by Sigyn Therapeutics (2000) Learn more about publishing your news release and our other news services on the Investorideas.com newswire https://www.investorideas.com/News-Upload/ and tickertagstocknews.com Global investors must adhere to regulations of each country. Please read Investorideas.com privacy policy: https://www.investorideas.com/About/Private_Policy.asp.

Follow us on Twitter https://twitter.com/Investorideas
Follow us on Facebook https://www.facebook.com/Investorideas
Follow us on YouTube https://www.youtube.com/c/Investorideas
Download our Mobile App for iPhone and Android
Join our Investor Club https://www.investorideas.com/membership/

Contact Investorideas.com

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/72688